The CLL-17 study, comparing continuous ibrutinib to time-limited therapies, showed overlapping efficacy. Its main impact wasn't declaring a winner, but affirming that oncologists can base treatment decisions on patient preference for continuous vs. fixed-duration therapy, knowing outcomes will be similar.
In current CLL practice, a positive MRD result after fixed-duration therapy does not trigger a change in treatment, such as extending therapy. It serves as a prognostic tool to inform the patient and physician about the likely duration of remission and the need for closer monitoring.
Adding obinutuzumab to acalabrutinib/venetoclax (triplet therapy) deepens responses but led to higher death rates in trials, partly due to COVID-19. This makes it a high-risk, high-reward strategy that experts reserve for younger, healthier patients with high-risk disease who prioritize coming off therapy.
In CLL, Progression-Free Survival (PFS) is a misleading metric for clinical benefit. Time-To-Next-Treatment (TTNT) is often much longer because patients can have biochemical or radiological progression by IWCLL criteria but remain asymptomatic and clinically well, delaying the need for a new therapy.
Higher death rates observed in the triplet therapy arms of recent CLL trials (e.g., AMPLIFY) were significantly impacted by the COVID-19 pandemic, as anti-CD20 antibodies increase infection risk. This historical context complicates the interpretation and generalizability of the toxicity data in a post-pandemic era.
The AMPLIFY regimen (acalabrutinib + venetoclax) has a built-in safety advantage. The initial two cycles of acalabrutinib monotherapy effectively debulk the disease, significantly reducing the risk of tumor lysis syndrome (TLS) when the potent BCL-2 inhibitor venetoclax is introduced later.
Using the non-covalent BTK inhibitor pirtobrutinib in the frontline setting poses a strategic risk. It can induce resistance mutations (e.g., T474I) that confer cross-resistance to both covalent and non-covalent BTK inhibitors, potentially eliminating an entire class of drugs for future use.
Subtle differences between second-generation BTK inhibitors like zanubrutinib and acalabrutinib lie in their pharmacokinetics. Zanubrutinib's ability to maintain drug concentration above the IC50 for the entire dosing interval may provide a theoretical advantage in highly proliferative disease by inhibiting newly synthesized BTK.
When a CLL patient progresses on a BTK inhibitor, experts may overlap it with venetoclax for a month or two. This practical, off-label approach leverages potential synergism and provides disease control while the venetoclax dose is being ramped up, before discontinuing the failing BTK inhibitor.